Miffee (Mifepristone)

Mifepristone, the active ingredient in Miffee, is a progesterone receptor antagonist presented as an oral formulation for oral use. It is employed in the medical termination of intrauterine pregnancy and in the management of Cushing's syndrome, with off‑label investigation for uterine fibroids. It is approved in the European Union for use under physician supervision.

GNH USA supplies Miffee as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Mifepristone acts on progesterone‑dependent pathways and is indicated for the following clinical situations: - Medical termination of intrauterine pregnancy: induces uterine contractions and facilitates expulsion of the gestational sac. - Management of Cushing's syndrome: blocks glucocorticoid receptors to reduce cortisol effects in selected patients. - Uterine fibroids (off‑label): investigated for reducing fibroid size by antagonizing progesterone signaling.

Mifepristone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may be transient. - Vaginal bleeding: irregular or prolonged spotting after medication. - Abdominal cramping: uterine pain or discomfort lasting several hours. - Fatigue: general tiredness and reduced energy levels.

Serious or Rare Side Effects: - Severe infection: signs of sepsis such as fever, chills, and rapid heart rate requiring urgent medical attention. - Heavy hemorrhage: excessive uterine bleeding that may necessitate transfusion or surgical intervention. - Liver injury: elevated liver enzymes, jaundice, or hepatitis‑like symptoms.

When prescribing Mifepristone, clinicians should observe several precautionary measures to ensure patient safety. - Confirm gestational age: ensure pregnancy is ≤10 weeks for approved use. - Evaluate contraindications: avoid in patients with chronic adrenal failure or uncontrolled infection. - Assess drug interactions: review concurrent use of CYP3A4 inducers or anticoagulants. - Monitor for bleeding: observe patients for signs of excessive hemorrhage after administration. - Provide follow‑up care: schedule clinical review to confirm complete expulsion and assess hormone levels. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Mifepristone interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with prostaglandin analogues.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase plasma concentrations. - Hormonal contraceptives: reduced efficacy when used concurrently. - Antidepressants (e.g., SSRIs): potential for altered metabolism, requiring observation.